| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA208: Trastuzumab for the treatment of HER2-positive metastatic gastric cancer |
|
Medicine details |
|
| Medicine name | trastuzumab (Herceptin®) |
| Formulation | powder for concentrate for solution for infusion |
| Reference number | 416 |
| Indication | In combination with capecitabine or 5-fluorouracil and cisplatin for the treatment of patients with HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction, who have not received prior anti-cancer treatment for their metastatic disease |
| Company | Roche Products Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 04/12/2009 |
| NICE guidance | TA208: Trastuzumab for the treatment of HER2-positive metastatic gastric cancer |